2.17
Esperion Therapeutics Inc stock is traded at $2.17, with a volume of 4.86M.
It is up +1.88% in the last 24 hours and up +77.87% over the past month.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
See More
Previous Close:
$2.13
Open:
$2.14
24h Volume:
4.86M
Relative Volume:
1.08
Market Cap:
$437.52M
Revenue:
$116.33M
Net Income/Loss:
$-209.25M
P/E Ratio:
-1.0236
EPS:
-2.12
Net Cash Flow:
$-135.49M
1W Performance:
+5.85%
1M Performance:
+77.87%
6M Performance:
+19.23%
1Y Performance:
+26.90%
Esperion Therapeutics Inc Stock (ESPR) Company Profile
Name
Esperion Therapeutics Inc
Sector
Phone
734-887-3903
Address
3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI
Compare ESPR with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
ESPR
Esperion Therapeutics Inc
|
2.17 | 423.41M | 116.33M | -209.25M | -135.49M | -2.12 |
![]()
ZTS
Zoetis Inc
|
156.62 | 67.51B | 9.39B | 2.62B | 2.22B | 5.81 |
![]()
TAK
Takeda Pharmaceutical Co Adr
|
15.52 | 47.88B | 29.96B | 957.25M | 4.77B | 0.304 |
![]()
HLN
Haleon Plc Adr
|
9.82 | 43.42B | 14.26B | 1.98B | 2.47B | 0.4347 |
![]()
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
18.46 | 20.72B | 16.70B | -157.13M | 1.19B | -0.155 |
![]()
UTHR
United Therapeutics Corp
|
312.23 | 14.21B | 2.99B | 1.21B | 1.13B | 25.06 |
Esperion Therapeutics Inc Stock (ESPR) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-18-24 | Initiated | Goldman | Neutral |
Dec-17-24 | Initiated | Cantor Fitzgerald | Overweight |
Jun-20-24 | Downgrade | BofA Securities | Neutral → Underperform |
Jan-03-24 | Downgrade | BofA Securities | Buy → Neutral |
Nov-20-23 | Resumed | JP Morgan | Neutral |
Aug-01-23 | Upgrade | Northland Capital | Under Perform → Market Perform |
Jun-15-23 | Upgrade | BofA Securities | Underperform → Buy |
Mar-16-23 | Downgrade | BofA Securities | Neutral → Underperform |
Mar-16-23 | Downgrade | Northland Capital | Market Perform → Under Perform |
Mar-07-23 | Upgrade | Credit Suisse | Underperform → Neutral |
Feb-27-23 | Resumed | BofA Securities | Neutral |
Feb-24-23 | Upgrade | Jefferies | Hold → Buy |
Feb-03-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
Aug-03-22 | Downgrade | Credit Suisse | Neutral → Underperform |
May-05-22 | Upgrade | JP Morgan | Underweight → Neutral |
Mar-10-22 | Initiated | H.C. Wainwright | Buy |
Oct-19-21 | Downgrade | Credit Suisse | Outperform → Neutral |
Oct-14-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
May-05-21 | Downgrade | Stifel | Buy → Hold |
Apr-26-21 | Resumed | Credit Suisse | Outperform |
Mar-11-21 | Initiated | Morgan Stanley | Equal-Weight |
Feb-12-21 | Downgrade | Jefferies | Buy → Hold |
Feb-09-21 | Downgrade | Goldman | Neutral → Sell |
Jan-15-21 | Downgrade | BofA Securities | Buy → Neutral |
Nov-10-20 | Upgrade | Credit Suisse | Neutral → Outperform |
Sep-29-20 | Resumed | JP Morgan | Underweight |
Aug-11-20 | Downgrade | Credit Suisse | Outperform → Neutral |
Apr-01-20 | Resumed | BofA/Merrill | Buy |
Mar-17-20 | Upgrade | Citigroup | Neutral → Buy |
Feb-24-20 | Downgrade | Northland Capital | Outperform → Market Perform |
Feb-14-20 | Downgrade | Citigroup | Buy → Neutral |
Sep-16-19 | Upgrade | Goldman | Sell → Neutral |
May-29-19 | Downgrade | Goldman | Neutral → Sell |
May-06-19 | Upgrade | BofA/Merrill | Underperform → Neutral |
Apr-26-19 | Upgrade | Goldman | Sell → Neutral |
Mar-13-19 | Upgrade | JP Morgan | Underweight → Neutral |
Jan-07-19 | Reiterated | Needham | Strong Buy |
Dec-13-18 | Initiated | Goldman | Sell |
Oct-29-18 | Upgrade | Northland Capital | Market Perform → Outperform |
Oct-16-18 | Initiated | BTIG Research | Buy |
Aug-17-18 | Upgrade | Citigroup | Neutral → Buy |
Jul-11-18 | Downgrade | Northland Capital | Outperform → Market Perform |
May-03-18 | Downgrade | JP Morgan | Neutral → Underweight |
May-02-18 | Downgrade | BofA/Merrill | Buy → Underperform |
View All
Esperion Therapeutics Inc Stock (ESPR) Latest News
Esperion rises after revenue beat, Q1 profitability expectation - MSN
Three Analyst Favorites with Potential for Further Gains: SkyWater Technology, Emergent BioSolutions, and More - AInvest
Detecting support and resistance levels for Esperion Therapeutics Inc.Stock Surge & Safe Entry Momentum Tips - Newser
Chart based analysis of Esperion Therapeutics Inc. trendsWeekly Market Report & AI Forecasted Entry/Exit Points - Newser
Is Esperion Therapeutics Inc. still worth holding after the dip2025 Short Interest & Community Consensus Picks - Newser
Esperion Therapeutics soars amid vague takeover speculation - MSN
Best data tools to analyze Esperion Therapeutics Inc. stockTrade Risk Report & Risk Controlled Daily Plans - Newser
Esperion Therapeutics Inc. stock outlook for YEARPortfolio Update Report & Stepwise Entry/Exit Trade Alerts - Newser
Is Esperion Therapeutics Inc. a Top Dividend Stock to Watch in 2025Market Movers & AI Based Trade Execution Alerts - Newser
Applying sector rotation models to Esperion Therapeutics Inc.Market Growth Summary & Free Low Drawdown Momentum Trade Ideas - Newser
Esperion Therapeutics (NASDAQ:ESPR) Upgraded at Wall Street Zen - Defense World
Pattern recognition hints at Esperion Therapeutics Inc. upsideStock Surge & Risk Adjusted Buy/Sell Alerts - Newser
What MACD signals say about Esperion Therapeutics Inc.July 2025 PostEarnings & Step-by-Step Swing Trade Plans - Newser
Real time scanner hits for Esperion Therapeutics Inc. explainedJuly 2025 Earnings & Smart Money Movement Alerts - Newser
Will Esperion Therapeutics Inc. price bounce be sustainableCEO Change & Daily Market Momentum Tracking - Newser
What the charts say about Esperion Therapeutics Inc. today2025 Price Targets & Long Hold Capital Preservation Tips - Newser
Is Esperion Therapeutics Inc. stock poised for growth2025 EndofYear Setup & Stock Portfolio Risk Control - Newser
Backtesting results for Esperion Therapeutics Inc. trading strategiesWeekly Gains Summary & Breakout Confirmation Trade Signals - Newser
Assessing Madrigal Pharmaceuticals' Long-Term Market Potential in the LDL-C Lowering Therapy Sector Amid Competitive Dynamics - AInvest
Is a relief rally coming for Esperion Therapeutics Inc. holdersDollar Strength & Free High Accuracy Swing Entry Alerts - Newser
Signal strength of Esperion Therapeutics Inc. stock in tech scannersJuly 2025 Update & Short-Term Trading Opportunity Alerts - Newser
Can Esperion Therapeutics Inc. Regain Momentum After BreakdownJuly 2025 Rallies & Safe Entry Trade Reports - beatles.ru
What earnings revisions data tells us about Esperion Therapeutics Inc.Quarterly Profit Review & Real-Time Buy Signal Notifications - Newser
Wall Street Zen Upgrades Esperion Therapeutics (NASDAQ:ESPR) to "Hold" - MarketBeat
Esperion Delays Q2 2025 Financial Report Filing - MSN
Competitive Positioning of Esperion Therapeutics Inc.: Is It Leading or LaggingFree Intraday Trend Analysis for Fast Gains - Newser
Published on: 2025-08-10 18:32:11 - beatles.ru
FY2025 EPS Estimates for ESPR Boosted by Cantor Fitzgerald - Defense World
Esperion Therapeutics Inc. At Decision Level — Rebound or ResistanceExpert Verified Stock Trade Ideas Backed by Data - beatles.ru
ESPR's Q2 Earnings & Revenues Trump Estimates, Stock Rises - MSN
Esperion Therapeutics (NASDAQ:ESPR) Upgraded to Hold at Wall Street Zen - Defense World
HC Wainwright Issues Positive Outlook for ESPR Earnings - Defense World
Published on: 2025-08-08 10:01:24 - beatles.ru
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) for New Employees - AInvest
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
Esperion Grants 73,500 RSUs with 4-Year Vesting Schedule to Attract Top Talent - Stock Titan
Esperion Therapeutics’ Earnings Call Highlights Growth - The Globe and Mail
Esperion (ESPR) Q2 Revenue Jumps 12% - AOL.com
Esperion Therapeutics (ESPR) Reports Q2 Loss, Tops Revenue Estimates - MSN
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q2 2025 Earnings Call Transcript - Insider Monkey
Esperion expects sustainable profitability in Q1 2026 as double-digit growth continues - MSN
Esperion Therapeutics: Q2 Earnings Snapshot - New Haven Register
What institutional flow reveals about Esperion Therapeutics Inc.Long-Term Stock Growth Forecast Insights - Newser
Esperion Therapeutics Inc (ESPR) Q2 2025 Earnings Call Highlights: Strong US Net Product ... By GuruFocus - Investing.com Canada
Esperion Therapeutics Reports Strong Q2 2025 Growth - TipRanks
Esperion Therapeutics Inc Stock (ESPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Esperion Therapeutics Inc Stock (ESPR) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Halladay Benjamin | Chief Financial Officer |
Jul 17 '25 |
Sale |
1.11 |
11 |
12 |
474,462 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):